Infinity Pharmaceuticals KOL Event: MARIO-3 TNBC Study Update and MARIO-275 UC Status Update
About The Event
The webinar will feature a presentation by Erika P. Hamilton, M.D. of Sarah Cannon Cancer Care and Research, who will present updated data from the MARIO-3 Phase 2 study in frontline patients with Triple Negative Breast Cancer (TNBC) in the context of the current standard of care. Dr. Hamilton presented the initial MARIO-3 TNBC data at SABCS 2020 and will be available to answer questions following the formal presentation.
Infinity’s Consulting Chief Physician, Dr. Schwartz, will present a status update on eganelisib in urothelial cancer (UC) building on the initial data from MARIO-275 Phase 2 study in second line patients with UC, which he presented at ASCO-GU in February 2021.
The MARIO-3 TNBC Phase 2 study in collaboration with Roche/Genentech is evaluating the addition of eganelisib to Tecentriq® and Abraxane®, the approved standard of care, in PD-L1 high 1L TNBC patients. The MARIO-275 UC Phase 2 study in collaboration with BMS is evaluating the addition of eganelisib to Opdivo®, the approved standard of care, in 2L UC patients who have progressed on a platinum therapy.
Eganelisib is a first-in-class, oral, once-daily, immuno-oncology macrophage reprogramming therapeutic.